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Is Drotrecogin alfa (activated) for adults with
severe sepsis, cost-effective in routine clinical
practice?
M Zia Sadique1*, Richard Grieve1, David A Harrison2, Brian H Cuthbertson3 and Kathryn M Rowan2
Abstract
Introduction: Previous cost-effectiveness analyses (CEA) reported that Drotrecogin alfa (DrotAA) is cost-effective
based on a Phase III clinical trial (PROWESS). There is little evidence on whether DrotAA is cost-effective in routine
clinical practice. We assessed whether DrotAA is cost-effective in routine practice for adult patients with severe
sepsis and multiple organ systems failing.
Methods: This CEA used data from a prospective cohort study that compared DrotAA versus no DrotAA (control)
for severe sepsis patients with multiple organ systems failing admitted to critical care units in England, Wales, and
Northern Ireland. The cohort study used case-mix and mortality data from a national audit, linked with a separate
audit of DrotAA infusions. Re-admissions to critical care and corresponding mortality were recorded for four years.
Patients receiving DrotAA (n = 1,076) were matched to controls (n = 1,650) with a propensity score (Pscore), and
Genetic Matching (GenMatch). The CEA projected long-term survival to report lifetime incremental costs per
quality-adjusted life year (QALY) overall, and for subgroups with two or three to five organ systems failing at
baseline.
Results: The incremental costs per QALY for DrotAA were £30,000 overall, and £16,000 for the subgroups with
three to five organ systems failing. For patients with two organ systems failing, DrotAA resulted in an average loss
of one QALY at an incremental cost of £15,000. When the subgroup with two organ systems was restricted to
patients receiving DrotAA within 24 hours, DrotAA led to a gain of 1.2 QALYs at a cost per QALY of £11,000. The
results were robust to other assumptions including the approach taken to projecting long-term outcomes.
Conclusions: DrotAA is cost-effective in routine practice for severe sepsis patients with three to five organ systems
failing. For patients with two organ systems failing, this study could not provide unequivocal evidence on the cost-
effectiveness of DrotAA.
Introduction
Severe sepsis is the most common cause of death for
patients admitted to critical care [1-3]. Recent interna-
tional studies suggest that the annual incidence of severe
sepsis is 50 to 100 cases per population of 100,000 [4].
Approximately 80% of critical care admissions with
severe sepsis have multiple organ systems failing, and
the associated hospital mortality is around 50%. Severe
sepsis is associated with substantial health-care costs; in
the US, the annual costs are approximately $17 billion
[1,5-9]. Severe sepsis survivors have a lower quality of
life than the age- and sex-matched general population
[10,11].
There is ongoing debate about the effectiveness of
severe sepsis therapies, including corticosteroids, inten-
sive insulin therapy, and Drotrecogin alfa (activated)
(DrotAA) (Xigris®; Eli Lilly and Company, Indianapolis,
IN, USA) (also known as a recombinant human acti-
vated protein C). In particular, although DrotAA has
been evaluated in several large, multicenter randomized
controlled trials (RCTs) [12,13], concerns remain about
the therapy’s effectiveness, both overall and for particu-
lar patient subgroups. In 2001, the PROWESS (Protein
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C Worldwide Evaluation in Severe Sepsis) trial reported
that a 96-hour intravenous infusion (24 μg/kg per hour)
of DrotAA versus placebo reduced absolute mortality at
28 days by 6.1% [13]. However, subgroup analysis of the
PROWESS trial suggested a benefit solely for ‘high risk’
patients, and the original US Food and Drug Adminis-
tration (FDA) license was limited to this subgroup; for
‘low risk’ patients, concerns about side-effects and lack
of benefit meant that a follow-up study was requested
[14,15]. The European Medical Evaluation Agency
(EMEA) license for DrotAA was granted under ‘excep-
tional circumstances’, indicating that the efficacy data
were limited and annual reassessment was required.
Both the FDA and the EMEA licensed DrotAA for use
in patients with severe sepsis at high risk of death but
differed in their definition of baseline risk of death.
High risk of death was defined by the US label as an
APACHE II (Acute Physiology and Chronic Health Eva-
luation II) score of 25 or more and by the European
Union label as the presence of multiple organ failure.
The subsequent ADDRESS (Administration of Drotreco-
gin alfa (activated) in Early Stage Severe Sepsis) trial
included solely ‘low risk’ patients but was stopped early
for futility [12]. A separate trial, RESOLVE (REsearching
severe Sepsis and Organ dysfunction in children: a gLo-
bal perspectiVE), was initiated to investigate the efficacy
and safety of DrotAA in children [16] but did not report
any beneficial effect of DrotAA and was also stopped
early. A new RCT, ‘PROWESS Shock’ [17], will provide
additional evidence on the efficacy of DrotAA for high-
risk patients, specifically those with septic shock, but
does not include a cost-effectiveness analysis (CEA).
For DrotAA, the relatively high drug costs - the acqui-
sition cost of a 96-hour infusion is around £5,900 (2010
prices) - and associated critical care stay and the trade-
off between potential benefit and risk mean that rigor-
ous CEA is particularly important. Previous studies
reported that DrotAA was cost-effective for adults with
severe sepsis [18-23], but because the studies were
based on PROWESS, these findings may not apply to
routine clinical practice. General concerns with the
RCTs for DrotAA are that they were tightly regulated,
included a narrow range of patients and centers, applied
restrictive treatment protocols, focused on short-term
endpoints (28-day mortality), and did not collect cost
data. These concerns make the RCTs unsuitable for
assessing the cost-effectiveness of DrotAA in routine
clinical practice. Furthermore, previous studies did not
assess the cost-effectiveness of DrotAA according to the
baseline risk of death or the timing of DrotAA adminis-
tration. Recent work has suggested that DrotAA may be
more effective if given within 24 hours of admission
[24,25].
In the absence of appropriate RCTs, CEA may use
observational data [26-28]. Recent observational studies
have compared outcomes for severe sepsis patients
receiving DrotAA with outcomes for matched controls
[4,29-36]. However, none of these studies assessed cost-
effectiveness. We report cost-effectiveness of DrotAA by
using data from a prospective cohort study that audited
outcomes following DrotAA in routine clinical practice
in England, Wales, and Northern Ireland [29].
This paper aims to assess the cost-effectiveness of
DrotAA in routine clinical practice versus control for
adult patients with severe sepsis and multiple organ sys-
tems failing. The results are presented both for the over-
all group (two to five organ systems failing within 24
hours of admission to the critical care unit) and for
high- or low-risk subgroups, defined according to the
number of organ systems failing (two or three to five).
Materials and methods
Overview
By extending a previous prospective cohort study [29], this
CEA compared DrotAA versus no DrotAA (control) for
adult patients who had severe sepsis or multiple organ sys-
tems failing and who were admitted to critical care units
in England, Wales, or Northern Ireland. In brief, the pre-
vious study used audit data from routine clinical practice
and applied inclusion and exclusion criteria based on
PROWESS [13]. Data for each severe sepsis patient, either
receiving DrotAA or not (controls), were linked to case
mix, resource use, and cost data from a national audit.
Patients receiving DrotAA were matched to controls.
Readmissions to critical care and mortality were recorded
for a follow-up period of 4 years. The study follows
method guidelines and extrapolates from the observed
data to report cost-effectiveness over the patients’ lifetime
[37]. Details of the data sources, estimation of costs and
outcomes, and analytical methods are given below.
Data source and DrotAA patients
The effectiveness and costs for patients receiving Dro-
tAA versus control were estimated with data from the
Case Mix Programme (CMP) coordinated by the Inten-
sive Care National Audit & Research Centre (ICNARC).
The CMP is a national comparative outcome audit and
includes 91% of the adult general (mixed medical and
surgical) critical care units (including intensive care,
combined intensive care, and high-dependency care
units) in England, Wales, and Northern Ireland. Pro-
spective data on case mix, resource use, and outcomes
were collected on consecutive admissions to each parti-
cipating critical care unit (see Harrison and colleagues
[38] for details). Case mix data were recorded within the
first 24 hours following unit admission and include age,
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physiological measures, medical history, surgical status,
and reason for admission. The physiology data are used
to calculate important prognostic measures for case mix
adjustment or subgroup analysis; these measures include
acute physiology score (ICNARC model), baseline pre-
dicted probability of death (ICNARC model), and the
number and type of organ systems failing within 24
hours following admission on the basis of PROWESS
definitions. CMP data have been assessed to be of high
quality and highly representative of all UK critical care
units [39]. Support for the collection and use of patient-
identifiable data without consent was obtained under
section 60 of the UK Health and Social Care Act of
2001 (approval number PIAG 2-10[f]/2005).
In December 2002, ICNARC conducted a large, multi-
center audit on the use of DrotAA and subsequent out-
come. Overall, 112 units (57% of those invited) actively
participated; these units were representative of all those
in the CMP. Each unit collected data on DrotAA use and
adverse events for each admitted patient who received
DrotAA at any time during their stay in the critical care
unit. To provide CMP data on case mix, resource use,
and outcomes, the DrotAA and CMP data were linked.
Patients who were admitted with severe sepsis and
multi-organ systems failing or who developed severe
sepsis and multi-organ systems failing during the first
24 hours in the critical care unit were identified by cri-
teria derived from PROWESS [13]. Severe sepsis was
defined as evidence of infection and three or more sys-
temic inflammatory response syndrome criteria. Multi-
organ systems failing was defined as two or more organ
systems failing (cardiovascular, respiratory, renal, hema-
tological, or metabolic) during the first 24 hours [29].
Each patient who met these criteria and received Dro-
tAA at a participating unit during the recruitment per-
iod was included (n = 1,076).
Controls
Controls were CMP database patients who were defined
as having severe sepsis and multiple organ systems fail-
ing during the first 24 hours following admission to cri-
tical care, according to the above criteria, but did not
receive DrotAA. Of the four potential control pools con-
sidered in the previous study [29], the control pool
judged a priori to have the patients and units most simi-
lar to those receiving DrotAA was chosen. The control
pool consisted of admissions contemporaneous to those
who received DrotAA in those critical care units that
went on to use DrotAA but who had not yet had their
first use of DrotAA in that unit (n = 1,650).
Costs
All hospital costs for the DrotAA and controls were
considered for the index hospital admission and for
readmissions to the original critical care unit over the
course of a 4-year period. Resource use data were
recorded and combined with unit costs.
Resource use measurement
Resource use data were collected on the duration of
DrotAA infusion, the length of stay (LOS) in critical
care, and the total LOS in acute hospital. Information
on the time at which DrotAA infusion was commenced
was recorded. Complete data on the duration of DrotAA
infusion were available for 90% of DrotAA cases; for the
remainder, it was known that the infusion was inter-
rupted; they were assumed to have the infusion for 48,
rather than 96, hours. Information on readmissions to
the original critical care unit for a 4-year period, follow-
ing the index admission, was available from the CMP
for each DrotAA and control. Details on the number of
readmissions and subsequent critical care and acute hos-
pital LOSs were extracted. It was assumed that, after 4
years, there were no further morbidity costs attributable
to the initial episode of severe sepsis [40].
Unit costs
Unit costs of DrotAA were taken from the National
Institute for Health and Clinical Excellence (NICE)
Health Technology Assessment (HTA) report [41]. For
all admissions, each critical care bed-day was categor-
ized according to the number of organ systems failing
and costed with the corresponding cost per bed-day
from the UK ‘Payment by Results’ database [42]. Costs
per bed-day in hospital after discharge from critical care
were taken from the literature [19]. All costs were
adjusted to 2010-2011 price levels [43]. Resource use
and unit costs were combined to report total costs per
patient over the lifetime for DrotAA patients and for
controls.
Outcomes
The main outcome measure was the quality-adjusted life
year (QALY) over the patient’s lifetime. This measure
required using data on mortality from the original criti-
cal care unit admission and ensuing hospital episode,
and from any subsequent readmissions to that critical
care unit, to project life years for each patient. These
estimated life years were combined with estimates of
health-related quality of life (HRQOL) [44] to project
lifetime QALYs for each patient.
Mortality
For the initial admission to critical care, information on
vital status at acute hospital discharge and the date of
death was taken from the CMP Database. For severe
sepsis patients surviving the initial acute hospital epi-
sode, information on mortality following readmission to
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the same critical care unit, over 4 years, was used to
reflect the excess risk of death in comparison with the
general population [40,45]. For each patient whose
death was recorded within those 4 years, the number of
life years was then calculated directly (from the differ-
ence between date of death and date of initial admis-
sion). Patients who survived the initial acute hospital
episode and all readmissions to the same critical care
unit were assumed to have the same life expectancy,
matched for age and gender, as the general population.
There is evidence to suggest that severe sepsis survivors
face a higher probability of death after the critical care
episode in comparison with the general population (age-
and gender-matched). However, there is no clear evi-
dence of the duration of this excess mortality; the stron-
gest evidence is in support of an excess mortality of up
to 5 years, although some previous work has applied
excess mortality for up to 25 years [46]. In our base
case analysis, we follow previous studies [40,45,47] and
take a conservative approach and apply the excess mor-
tality for up to 4 years (see subsequent sensitivity
analysis).
Health-related quality of life
HRQOL for critical care survivors is lower than that for
the general population after matching for age and gen-
der [45,47,48]. We therefore down-weighted age- and
gender-specific HRQOL weights from the general popu-
lation [49]. We assumed, on the basis of the best avail-
able evidence from the literature [45], that HRQOL for
critical care survivors was 80% that of the general popu-
lation. We applied, on the basis of this long-term study,
this adjustment factor for the 4 years following the
initial admission, after which, HRQOL weights from the
general population were applied (see subsequent sensi-
tivity analysis, in which length of decrement of HRQOL
is varied). Lifetime QALYs were reported by combining
life years and HRQOL. Future QALYs and costs were
discounted at the recommended rate of 3.5% [37].
Analysis
Matching
Matched cohort analyses were performed; initially, this
was done according to a propensity score (Pscore). The
Pscore model was similar to that developed previously
[29] and estimated the probability of receiving DrotAA
with a logistic regression model that included both
patient and critical care unit level baseline factors. Unit
factors included were hospital type and number of criti-
cal care beds. Patient factors included were as follows:
age, ICNARC model physiology score (IMscore), gender,
number of organ systems failing, specific organ failures
(cardiovascular, respiratory, renal, hematological, and
metabolic acidosis), source of admission to critical care
(via the emergency department, theater or recovery,
ward, clinic or home), diagnostic category (ICNARC
Coding Method) [50], and serious condition in the med-
ical history [29]. Age and IMscore were defined as non-
linear terms fitted as smoothed functions by using
restricted cubic splines [51]; other continuous measures
were assumed to have linear relationships with treat-
ment assignment.
We then applied Genetic Matching (GenMatch),
which extends Pscore matching by using an automated
search algorithm to choose the best matches, which are
those that maximize the balance in the distribution of
baseline characteristics between the treatment and con-
trol groups [28,52-55]. The explicit aim of GenMatch is
to maximize balance according to statistics such as t
tests or standardized differences in means. GenMatch
matches on the Pscore but also matches on individual
factors and can achieve better balance than matching on
the Pscore alone [28,52-55]. A key advantage versus
Pscore approaches is that GenMatch matches directly
on any individual covariates judged to be potential con-
founders. Both methods matched one-to-one with repla-
cement. So that average treatment effects could be
estimated, each DrotAA case was matched to a control,
and the remaining unmatched controls were each
matched to a DrotAA case [56]. For both approaches,
we reported balance on those variables previously
judged to be important potential confounders [29]; these
were age, gender, serious conditions in the medical his-
tory, acute physiology score (ICNARC model), predicted
probability of acute hospital mortality (ICNARC model),
proportion receiving mechanical ventilation, and num-
ber and types of organ systems failing during the first
24 hours in critical care. We reported covariate balance
for the overall sample of DrotAA patients versus con-
trols. Balance was measured with standardized mean dif-
ference; a difference of greater than 10% was taken to
indicate meaningful imbalance [57,58]. Both matching
methods were initially performed on the full sample of
DrotAA patients and controls to report overall cost-
effectiveness.
We categorized patients a priori into two subgroups
according to the number of organ systems failing during
the first 24 hours in critical care: two organ systems fail-
ing (low-risk subgroup) and three to five organ systems
failing (high-risk subgroup). These particular subgroup
definitions were adopted previously [29,41]. We
matched DrotAA patients and controls with both
matching methods, separately for each subgroup, and
reported the resultant balance statistics at the subgroup
level.
Statistical analysis
The aim of the statistical analysis was to report the
incremental effectiveness, costs, and cost-effectiveness of
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DrotAA versus control. We reported average treatment
effect for the overall group of patients (two or more
organ systems failing at baseline) and for the a priori-
defined subgroups of patients with two or with three to
five organ systems failing. We reported the incremental
effectiveness for DrotAA versus control as the odds
ratio of acute hospital mortality at initial admission by
applying logistic regression to the matched data. We
compared mean costs and QALYs over the lifetime
(DrotAA versus control). The CEA reported incremental
cost-effectiveness ratios (ICERs) (costs per QALY) and
incremental net benefits (INBs) [59] of DrotAA versus
control. The INBs were calculated by valuing incremen-
tal QALYs according to the recommended level of will-
ingness to pay for a QALY in the UK (£20,000 per
QALY [37]) and subtracting from this the incremental
costs.
Statistical uncertainty around the incremental results
was considered by reporting 95% confidence intervals
(CIs) by using the non-parametric bootstrap [60] on the
matched data. One thousand bootstrap samples of the
mean effectiveness and the mean costs were generated.
The bootstrap recognized the correlation between costs
and outcomes by bivariate re-sampling, and the re-sam-
pling also stratified by treatment group. Incremental
costs, incremental effects, and INB were calculated from
the bootstrap sample. A cost-effectiveness acceptability
curve [61] was constructed to report the probability that
DrotAA was cost-effective at alternative levels of willing-
ness to pay for a QALY gained.
Sensitivity analysis
The base case made the following assumptions that,
while conservative, were judged to be potentially impor-
tant: (a) GenMatch was the most appropriate matching
method, (b) it was appropriate to include all DrotAA
cases irrespective of the time infusion commenced, (c)
DrotAA patients who did not have a complete duration
of infusion and survived were assumed to have received
50% (48 hours) of the full infusion, (d) the excess mor-
tality associated with severe sepsis was assumed for 4
years after critical care discharge, and (e) the decrement
in quality of life for severe sepsis was applied for 4 years
after hospital discharge. The sensitivity analyses tested
whether the base case results were robust if the follow-
ing alternative standpoints were taken:
Pscore matching To test whether the results were sensi-
tive to the matching method, cost-effectiveness esti-
mates were reported after Pscore matching rather than
GenMatch.
Timing of DrotAA infusion This sensitivity analysis
included only those DrotAA patients whose infusion
was commenced within 24 hours of admission. This
restricted sample was re-matched by using data from
the original pool of controls. The main purpose of the
sensitivity analysis was to assess whether the base case
results were sensitive to potential for hidden bias in
those treated with delay.
DrotAA drug cost It was assumed that patients who did
not receive full infusion of DrotAA and were discharged
alive from critical care received 75% (72 hours) of the
full DrotAA infusion.
Duration of excess mortality The period of excess
mortality was extended beyond the 4 years applied in
the base case. Alternative data suggest that, for critical
care survivors, excess mortality could continue for up to
25 years [46]. In this sensitivity analysis, the magnitude
of excess death rates for an extended period of time (25
years) was taken from a previous study [46] and applied
to patients who survived the initial acute hospital epi-
sode and all readmissions to the same critical care unit.
These excess death rates relative to age- and gender-
matched mortality in the general population were
applied beyond 4 years for up to 25 years.
Health-related quality of life decrement The HRQOL
decrement was assumed to be maintained up to 25
rather than 4 years [46].
Health-related quality of life of critical care survivors
The HRQOL of critical care survivors was varied 70% to
90% to that of the general population rather than 80%
assumed in the base case.
Results
Covariate balance
Before matching, DrotAA patients were, on average,
younger (standardized difference of 29%) and had a
higher acute physiology score (standardized difference of
50%) and a higher baseline probability of acute hospital
death (standardized difference of 30%) in comparison
with controls (Table 1). After both Pscore matching and
GenMatch, the baseline characteristics were similar
between the treatment groups, but the standardized dif-
ferences were generally lower following GenMatch
(Table 1). For the subgroups of patients with two (Table
2a) and three to five (Table 2b) organ systems failing,
patient characteristics were well balanced after Gen-
Match; additional covariates were also evenly distributed
between the treatment groups (Additional data file 1).
As GenMatch achieved better balance than Pscore
matching, further results are reported for GenMatch
only.
Outcomes - mortality
Table 3 reports odds ratios for the effect of DrotAA on
acute hospital mortality within the initial admission. For
the overall sample, the odds ratios of death for DrotAA
versus control are less than 1 both before and after
matching. For the subgroup with two organ systems fail-
ing, DrotAA was associated with increased hospital
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Table 1 Patient characteristics before and after propensity score matching and Genetic Matching
Mean/percentagea
DrotAA
(n = 1,076)
Mean/percentagea
Control
(n = 1,650)
Percent standardized
difference
Age (year)s
Unmatched 58.70 64.35 28.85
Pscore match 61.48 61.90 2.55
GenMatch 62.22 62.23 0.06
ICNARC model acute physiology score
Unmatched 30.38 25.09 50.16
Pscore match 27.24 27.18 0.63
GenMatch 27.15 27.15 0.08
Serious conditions in medical history (percentage)
Cardiovascular
Unmatched 0.47 1.82 11.63
Pscore match 1.05 1.39 3.09
GenMatch 1.28 1.28 0.00
Respiratory
Unmatched 2.14 3.39 6.50
Pscore match 2.71 3.02 1.85
GenMatch 1.72 2.64 2.22
Renal
Unmatched 1.12 2.36 8.31
Pscore match 1.10 1.87 6.33
GenMatch 1.14 1.94 2.32
Liver
Unmatched 0.84 1.58 5.84
Pscore match 5.53 1.52 21.88
GenMatch 1.14 1.28 0.47
Immunosuppressed
Unmatched 7.25 10.55 9.75
Pscore match 11.35 9.80 5.06
GenMatch 5.61 8.58 4.10
ICNARC model predicted probability of acute hospital mortality
Unmatched 0.60 0.51 30.31
Pscore match 0.55 0.55 0.21
GenMatch 0.55 0.55 0.06
Number of organ systems failing during first 24 hours of stay in
critical care (percentage)
Two
Unmatched 18.40 38.18 38.20
Pscore match 32.15 30.27 4.05
GenMatch 29.35 29.79 0.34
Three
Unmatched 40.06 38.91 1.91
Pscore match 37.47 41.22 7.69
GenMatch 38.11 41.16 2.20
Four
Unmatched 33.55 18.12 28.31
Pscore match 25.33 21.48 9.10
GenMatch 26.85 22.71 3.40
Five
Unmatched 7.99 4.79 10.33
Pscore match 5.05 7.03 8.30
GenMatch 5.69 6.35 0.98
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mortality, and the odds ratio after matching was 1.56
(95% CI of 1.25 to 1.85). For the subgroup with three or
more organ systems failing, DrotAA was associated with
reduced hospital mortality (odds ratio following match-
ing of 0.61, 95% CI of 0.53 to 0.79). The matching has
balanced those potential confounders that are observed;
for the subgroup with two organ systems failing, the
result is that DrotAA is associated with an increase in
hospital mortality in excess of 10%.
The mean total costs of the initial hospital admission
episode were about £32,000 and £15,000 for the DrotAA
and control groups (Table 4). The additional costs for
DrotAA comprised drugs costs but also additional days
in critical care (mean of 15 versus 7.5 days for controls)
(Additional data file 2). These additional days in critical
care for DrotAA were observed for both survivors
(mean of 17 versus 9 days) and decedents (mean of 11
versus 5 days). Approximately 10% of both DrotAA
patients and controls were readmitted over the course
of 4 years (Additional data file 3); hence, readmission
costs were similar across the groups. Similarly, for both
subgroups, DrotAA was associated with higher costs
during the initial acute hospital stay (Table 4).
Lifetime cost-effectiveness results
The lifetime incremental cost-effectiveness results are
reported in Table 5. For the overall sample, the incre-
mental costs for DrotAA were £18,000 and the QALY
gain was 0.60, leading to an ICER of £30,158 per QALY.
The QALY gain of 0.6 valued at £20,000 led to an INB
of -£6,000 (0.6*20,000-18,000). For patients with two
organ systems failing, the higher mortality associated
with DrotAA led to an average loss of one QALY,
which, coupled with the positive incremental costs, led
to a negative INB (-£35,000). For the subgroup with
three to five organ systems failing, the incremental
QALY for DrotAA was relatively high (mean QALY
gain of 1.3), the ICER was relatively low (£15,561), and
the corresponding INB was positive (£6,000) (Table 5).
The statistical uncertainty around the CEA results is
summarized in the cost-effectiveness acceptability curves
in Figure 1. The probabilities that DrotAA is cost-effec-
tive at a threshold of £20,000 per QALY are 5% for the
overall sample, 0% for the subgroup with two organ sys-
tems failing, and 99% for the subgroup with three or
more organ systems failing.
Sensitivity analysis
The impact on the base case results of matching just
with the Pscore rather than the individual covariates
(GenMatch), of limiting DrotAA to within 24 hours, of
increasing the drug cost, and of changing the duration
of excess mortality and HRQOL decrement are shown
in Table 6. When the sample was restricted to those
who received DrotAA during the first 24 hours in criti-
cal care, the DrotAA cases were reduced by 36%. For
this subsample, acute hospital mortality following Dro-
tAA was reduced, particularly for the subgroup with
Table 1 Patient characteristics before and after propensity score matching and Genetic Matching (Continued)
Organ systems failing during first 24 hours of stay in critical careb
(percentage)
Cardiovascular/Respiratory
Unmatched 14.03 25.27 24.24
Pscore match 23.38 20.74 6.37
GenMatch 23.51 20.73 2.38
Cardiovascular/Respiratory/Acidosis
Unmatched 33.27 28.49 8.41
Pscore match 28.49 32.32 8.33
GenMatch 32.06 32.80 0.55
Cardiovascular/Respiratory/Renal/Acidosis
Unmatched 25.37 12.30 26.50
Pscore match 18.50 15.40 8.25
GenMatch 19.15 16.25 2.69
Mechanical ventilation on admission or during first 24 hours of stay
in critical care (percentage)
Unmatched 92.47 75.33 42.51
Pscore match 83.32 82.32 0.93
GenMatch 82.25 82.21 0.03
a Mean reported for continuous variable and percentage for categorical variable
bFor the types of organ failure, results are presented for the most prevalent type for each number of organ failures; results for other types of organ failure are
presented in Additional file 1. DrotAA, Drotrecogin alfa (activated); GenMatch, Genetic Matching; ICNARC, Intensive Care National Audit & Research Centre; Pscore,
propensity score.
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Table 2 Patient characteristics before and after Genetic Matching for each subgroup
Mean/
percentagea
DrotAA
Mean/
percentagea
Control
Percent standardized
difference
a. Subgroup with two organ systems failing (n = 198) (n = 630)
Age (year)s
Unmatched 57.58 63.04 26.49
GenMatch 61.76 61.82 0.37
ICNARC model acute physiology score
Unmatched 22.83 20.44 29.53
GenMatch 20.86 20.88 0.35
Serious conditions in medical history, percentage
Cardiovascular
Unmatched 1.01 1.75 5.40
GenMatch 1.57 1.57 0.00
Respiratory
Unmatched 4.55 4.13 1.67
GenMatch 2.78 3.87 2.15
Renal
Unmatched 2.02 3.81 9.17
GenMatch 1.09 3.14 5.06
Liver
Unmatched 1.52 1.27 1.69
GenMatch 1.33 1.33 0.00
Immunosuppressed
Unmatched 7.07 6.98 0.28
GenMatch 4.59 6.16 2.46
ICNARC model predicted probability of acute hospital mortality
Unmatched 0.42 0.39 10.76
GenMatch 0.39 0.39 0.37
Organ systems failing in first 24 hoursb (percentage) - Cardiovascular/Respiratory
Unmatched 76.26 66.19 18.61
GenMatch 75.60 69.69 4.70
Mechanical ventilation (percentage)
Unmatched 88.38 70.16 40.02
GenMatch 75.24 75.12 0.10
b. Subgroup with three to five organ systems failing (n = 878) (n = 1,020)
Age (years)
Unmatched 58.96 65.16 32.32
GenMatch 62.46 62.47 0.00
ICNARC model acute physiology score
Unmatched 32.08 27.96 40.83
GenMatch 29.84 29.84 0.01
Serious conditions in medical history (percentage)
Cardiovascular
Unmatched 0.34 1.86 13.58
GenMatch 0.58 1.11 2.04
Respiratory
Unmatched 1.60 2.94 7.78
GenMatch 1.42 2.21 2.09
Renal
Unmatched 0.91 1.47 4.39
GenMatch 0.90 1.21 1.10
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two organ systems failing (Additional data file 4). Here,
the odds ratio for DrotAA versus control was 0.64 (95%
CI of 0.50 to 0.78), resulting in a QALY gain of 1.2 and
an ICER of £11,000. As the accompanying cost-effective-
ness acceptability curve shows, if the sample is limited
to those commencing DrotAA within 24 hours, then the
probability that the intervention is cost-effective exceeds
0.90 for both subgroups, irrespective of the willingness
to pay for a QALY gained (Figure 2). The results were
robust to the other main assumptions made in the base
case (Table 6).
Discussion
This study reports the cost-effectiveness of DrotAA in
routine clinical practice for adult severe sepsis patients
admitted to critical care units in England, Wales, and
Northern Ireland. The results suggest that DrotAA is
cost-effective for patients at high risk of acute hospital
death (three to five organ systems failing during the first
24 hours in critical care). For patients with two organ
systems failing, the results are less clear; whereas the
base case finding suggested that DrotAA was not cost-
effective, the sensitivity analysis suggested that the inter-
vention was cost-effective if limited to those patients
who received DrotAA within 24 hours.
This study extends previous CEAs of DrotAA by using
data from a large sample of units delivering routine clin-
ical care; previous CEAs used PROWESS data
[18-23,62]. Our approach allows cost-effectiveness
results to be presented for patients with characteristics
relevant to a more general population with severe sepsis.
We also report CEA results for patient subgroups
defined according to the number of organ systems fail-
ing, reflecting different baseline risks of death. There is
no consensus on how best to define risk for patients
with severe sepsis; some recommendations, notably in
Table 2 Patient characteristics before and after Genetic Matching for each subgroup (Continued)
Liver
Unmatched 0.68 1.77 8.70
GenMatch 1.16 1.16 0.00
Immunosuppressed
Unmatched 7.29 12.75 15.55
GenMatch 6.11 9.80 4.83
ICNARC model predicted probability of acute hospital mortality
Unmatched 0.64 0.58 20.12
GenMatch 0.61 0.61 0.00
Number of organ systems failing during first 24 hours of stay in critical care
(percentage)
Three
Unmatched 49.09 62.94 22.88
GenMatch 54.69 56.74 1.46
Four
Unmatched 41.12 29.31 20.07
GenMatch 36.57 34.14 1.79
Five
Unmatched 9.80 7.75 5.82
GenMatch 8.75 9.12 0.46
Organ systems failing during first 24 hours of stay in critical careb (percentage)
Cardiovascular/Respiratory/Acidosis
Unmatched 40.77 46.08 8.77
GenMatch 44.10 43.99 0.08
Cardiovascular/Respiratory/Renal/Acidosis
Unmatched 31.09 19.90 20.64
GenMatch 25.76 24.97 0.64
Mechanical ventilation on admission or during first 24 hours of stay in critical
care (percentage)
Unmatched 93.39 78.53 38.90
GenMatch 85.51 85.51 0.00
a Mean reported for continuous variable and percentage for categorical variable.
bFor the types of organ failure, results are presented for the most prevalent type for each number of organ failures; results for other types of organ failure are
presented in Additional file 1. DrotAA, Drotrecogin alfa (activated); GenMatch, Genetic Matching; ICNARC, Intensive Care National Audit & Research Centre.
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the US, favor the use of APACHE II score [63], whereas
others prefer the number of organ systems failing
[29,41]. More generally, there is a clear consensus that,
as in this study, subgroups should be defined a priori
[41]. This study also extends previous CEAs of DrotAA
by capturing important aspects of the longer-term
impact of DrotAA in that readmissions and accompany-
ing mortality are recorded for 4 years. This provides a
more robust basis for extrapolating long-term outcomes
than previous approaches [18,19,21].
Table 3 Acute hospital mortality and odds ratios for acute hospital mortality for all patients and for each subgroup
before and after Genetic Matching
DrotAA
n/N
(percentage)
Control
n/N
(percentage)
Odds ratio (95% CI) for acute hospital mortality for DrotAA versus
control
Overall: two to five organ systems
failing
Unmatched 490/1,076
(45.54)
817/1,650
(49.52)
0.85 (0.72, 0.98)
GenMatch 508/1,076
(47.25)
875/1,650
(53.04)
0.79 (0.71, 0.87)
Two organ systems failing
Unmatched 80/198 (40.40) 221/630 (35.08) 1.26 (0.81, 1.67)
GenMatch 93/198 (46.98) 228/630 (36.23) 1.56 (1.25, 1.85)
Three to five organ systems failing
Unmatched 410/878 (46.70) 596/1,020
(58.43)
0.62 (0.51, 0.74)
GenMatch 423/878 (48.16) 616/1,020
(60.38)
0.61 (0.53, 0.69)
CI, confidence interval; DrotAA, Drotrecogin alfa (activated); GenMatch, Genetic Matching.
Table 4 Costs, in pounds sterling, of initial hospital episode and readmissions within 4 years
DrotAA, mean (SD) Control, mean (SD)
Overall: two to five organ systems failing
Drug cost 5,022 (1,688) 0 (0)
ICU costs 21,204 (19,660) 10,692 (13,533)
Hospital costs 5,812 (9,145) 4,411 (7,884)
Total initial episode costs 32,038 (24,285) 15,102 (16,787)
ICU readmission costs 1,729 (8,252) 1,276 (5,987)
Hospital costs 2,281 (14,694) 2,054 (11,646)
Total readmission costs 4,010 (21,380) 3,330 (16,057)
Two organ systems failing
Drug cost 5,328 (1,338) 0 (0)
ICU costs 17,364 (15,564) 8,806 (9,142)
Hospital costs 5,933 (8,889) 4,998 (7,168)
Total initial episode costs 28,625 (19,810) 13,804 (12,108)
ICU readmission costs 914 (3,941) 916 (3,894)
Hospital costs 1,652 (5,225) 1,667 (8,538)
Total readmission costs 2,567 (8,202) 2,684 (11,308)
Three to five organ systems failing
Drug cost 4,916 (1,773) 0 (0)
ICU costs 22,853 (20,504) 11,692 (14,921)
Hospital costs 5,776 (9,496) 3,967 (7,898)
Total initial episode costs 33,544 (25,342) 15,659 (18,311)
ICU readmission costs 2,152 (9,978) 1,120 (5,604)
Hospital costs 2,823 (20,799) 1,794 (11,361)
Total readmission costs 4,976 (28,531) 2,914 (15,488)
Overall (two to five organ systems failing): total number = 2,726, Drotrecogin alfa (activated) (DrotAA) = 1,076, control = 1,650; two organ systems failing: total
number = 828, DrotAA = 198, control = 630; three to five organ systems failing: total number = 1,898, DrotAA = 878, control = 1,020. ICU, intensive care unit.
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A further strength of this study is that it uses appro-
priate methods to address selection bias by applying
both Pscore matching and GenMatch, which are recom-
mended approaches for addressing baseline differences
between treatment groups in potential confounding fac-
tors. Both Pscore and GenMatch achieved good balance
on key prognostic factors, and GenMatch achieved
excellent balance both overall and for each subgroup.
Hence, the possibility of bias arising from differences in
observed factors was minimized.
Short-term mortality estimates of this study are
broadly consistent with those from PROWESS. We
found that DrotAA reduced absolute acute hospital
mortality by 5.8% in comparison with a 6.1% reduction
in 28-day mortality in the PROWESS study. Our odds
ratios (0.79, 95% CI 0.71 to 0.87) are slightly less favor-
able for DrotAA than in PROWESS (0.8, 95% CI 0.69 to
0.94). The somewhat smaller effect of DrotAA on mor-
tality leads to lower lifetime QALY gains compared with
those of previous studies based on PROWESS
[18,19,21,22,62]. Our lifetime incremental costs of Dro-
tAA (£18,000) exceeded previous estimates (less than
£6,000) [19,21,62], which reflected the relatively high
initial LOS for DrotAA patients managed in routine
clinical practice (mean of 15 days for DrotAA versus 7.5
days for the control group). Consequently, our estimates
of the long-term cost-effectiveness of DrotAA are less
favorable than those previously reported [18,22]. Dhai-
naut and colleagues [64], applying Pscore matching, also
observed less favorable cost-effectiveness ratios; the
authors reported a cost per QALY of €34,000 in routine
clinical practice in France.
When methodological guidelines are followed and
cost-effectiveness results are reported over the lifetime,
assumptions inevitably have to be made. Our sensitivity
analysis suggested that the findings, with one exception,
were generally insensitive to the assumptions made. The
base case results reported that DrotAA was not cost-
effective for the subgroup with two organ systems fail-
ing. If the sample is limited to those cases receiving
DrotAA administered early (within 24 hours of admis-
sion), then the intervention, on average, reduces mortal-
ity for the subgroup with two organ systems failing and
becomes cost-effective. Several other studies have indi-
cated the benefit of early treatment. The ENHANCE
(Extended Evaluation of Recombinant Human Activated
Table 5 Lifetime costs in pounds sterling, quality-adjusted life years, and incremental net benefits in pounds sterling
after Genetic Matching
DrotAA, mean (SD) Control, mean (SD) Incremental, mean (95% CI)
Overall: two to five organ systems failing
Lifetime costs 36,048 (35,522) 18,432 (26,708) 17,616 (15,959 to 19,273)
Lifetime QALYs 5.70 (6.57) 5.11 (6.61) 0.58 (0.24 to 0.93)
INBa 77,896 (131,138) 83,830 (129,324) -5,934 (-12,735 to 868)
Two organ systems failing
Lifetime costs 31,191 (21,959) 16,488 (18,399) 14,703 (12,763 to 16,644)
Lifetime QALYs 5.87 (6.54) 6.83 (6.75) -0.97 (-1.62 to -0.32)
INBa 86,117 (130,821) 120,148 (134,047) -34,031 (-47,028 to -21,034)
Three to five organ systems failing
Lifetime costs 38,520 (43,205) 18,572 (27,266) 19,948 (17,610 to 22,286)
Lifetime QALYs 5.63 (6.59) 4.35 (6.33) 1.28 (0.86 to 1.70)
INBa 74,038 (132,559) 68,348 (122,496) 5,690 (-2,543 to 13,924)
Overall (two to five organ systems failing): total number = 2,726, Drotrecogin alfa (activated) (DrotAA) = 1,076, control = 1,650; two organ systems failing: total
number = 828, DrotAA = 198, control = 630; three to five organ systems failing: total number = 1,898, DrotAA = 878, control = 1,020. aIncremental net benefits
(INBs) are calculated by following method guidance [36] and multiplying the mean quality-adjusted life year (QALY) gain (or loss) by £20,000 and subtracting
from this the incremental cost. CI, confidence interval; SD, standard deviation.
Figure 1 Cost-effectiveness acceptability curves. The curves
show the probability that the intervention is cost-effective at
different levels of willingness to pay for a quality-adjusted life year
gain. DrotAA, Drotrecogin alfa (activated).
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Protein C) trial showed that treatment within 24 hours
of organ failure with DrotAA was associated with 23%
lower odds of death at 28 days in comparison with
treatment more than 24 hours after sepsis-induced
organ failure [25]. Others also have suggested that Dro-
tAA is more effective when administered early [24,29].
This study has several limitations. Firstly, we assumed
that acute hospital survivors who were not readmitted to
critical care faced a death rate equal to that of the general
population (age- and gender-matched), and this may have
underestimated deaths in this specific group of patients.
Our estimated death rates were similar to those used pre-
viously; for example, our overall projected mortality at 5-
year follow-up was 49% versus 47% in Wright and collea-
gues [40]. Furthermore, the sensitivity analysis finds that
the CEA results are insensitive to this assumption. Sec-
ondly, like other investigators attempting to report life-
time cost-effectiveness, we had to make plausible
assumptions about the long-term HRQOL; we tested
these assumptions in the sensitivity analysis and found
that they had little impact on the results. Thirdly,
unbiased treatment effects from matching are based on
the assumption of no hidden bias; this assumption might
be less tenable for the subgroup with two organ systems
failing, in which 36% of the DrotAA cases are treated
after a delay of more than 24 hours. There is some lim-
ited evidence from the FDA post hoc analysis [15] and
ADDRESS trial [12] to suggest that DrotAA may increase
mortality in subgroups with low baseline risk. However,
our sensitivity analysis suggested that, if the sample was
limited to those treated within 24 hours, DrotAA was
more effective and was cost-effective for the subgroup
with two organ systems failing. Here, the case severity at
the time DrotAA infusion commenced might have been
worse than that measured at baseline and used in the
matching. This suggests that either the base case findings
for the subgroup with two organ systems failing is prone
to hidden bias or DrotAA is more effective and cost-
effective for this subgroup if administered early. Further
research is required to focus specifically on the effective-
ness and cost-effectiveness of DrotAA administration for
patients at low levels of baseline severity and according
to the timing of therapy initiation.
Conclusions
This CEA, based on a prospective cohort study, suggests
that, in routine clinical practice, DrotAA is cost-effective
for severe sepsis patients with three or more organ sys-
tems failing within 24 hours of admission to a critical
care unit. For patients with two organ systems failing,
Figure 2 Cost-effectiveness acceptability curves for DrotAA
within 24 hours of critical care admission. The curves show the
probability that the intervention is cost-effective at different levels of
willingness to pay for a quality-adjusted life year gain for the
subsample who received Drotrecogin alfa (activated) (DrotAA)
within 24 hours of admission to the critical care unit.
Table 6 Sensitivity analysis on incremental net benefits in pounds sterling
Overall: two to five organ
systems failing
Two organ systems failing Three to five organ
systems failing
Base case -5,934 (-12,735 to 868) -34,031 (-47,028 to -21,034) 5,690 (-2,543 to 13,924)
Pscore matching -7,641 (-13,213, -2,069) -32,846 (-44,704, -20,987) 391 (-6,350, 7,133)
DrotAA given within 24 hoursa 8,078 (733 to 15,423) 11,131 (-2,173 to 24,435) 12,387 (3,491 to 21,283)
Cost of drug (alternative assumption) -4,687 (-11,544 to 2,171) -33,232 (-46,309 to -20,154) 7,339 (-976 to 15,653)
Excess mortality up to 25 years -6,240 (-12,897 to 418) -33,580 (-46,300 to -20,860) 5,046 (-3,012 to 13,104)
Excess reduction in HRQOL up to 25 years -7,240 (-13,328 to -1,152) -31,895 (-43,509 to -20,280) 2,863 (-4,512 to 10,237)
HRQOL of critical care survivors is 70% that of
general population
-6,029 (-12,679 to 621) -32,176 (-44,912 to -19,440) 4,839 (-3,202 to 12,880)
HRQOL of critical care survivors is 90% that of
general population
-5,347 (-12,254 to 1,560) -33,134 (-46,353 to -19,915) 6,239 (-2,117 to 14,596)
Values are presented as mean (95% confidence interval). Incremental net benefits are calculated by multiplying the mean quality-adjusted life year gain (or loss)
by £20,000 and subtracting from this the incremental cost. aOverall (two to five organ systems failing): total number = 2,337, Drotrecogin alfa (activated) (DrotAA)
= 687, control = 1,650; two organ systems failing: total number = 727, DrotAA = 97, control = 630; three to five organ systems failing: total number = 1,610,
DrotAA = 590, control = 1,020. HRQOL, health-related quality of life; Pscore, propensity score.
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this study could not provide unequivocal evidence on
the cost-effectiveness of DrotAA.
Key messages
• Drotrecogin alfa (activated), or DrotAA, is cost-
effective in routine practice for severe sepsis patients
with three to five organ systems failing during the
first 24 hours in critical care.
• For patients with two organ systems failing, it is
unclear whether DrotAA is cost-effective.
• Further research is required on the effectiveness
and cost-effectiveness of DrotAA administration for
patients at low levels of baseline severity and accord-
ing to the timing of therapy initiation.
Additional material
Additional file 1: Additional patients’ characteristics before and
after Pscore matching and GenMatch. Balance statistics of additional
covariates are shown.
Additional file 2: Length of stay (days) in critical care at index
admission - mean (sd). Shown is the length of stay in critical care in
DrotAA and control before and after GenMatch.
Additional file 3: Readmission to original critical care unit within 4
years (n/N(%)) and mortality at readmission (n/N(%)). Readmissions
and observed deaths in four years in original critical care unit are shown.
Additional file 4: Odds ratio, lifetime costs (£), QALYs, incremental
net benefits (INB) (£) mean (95% CI) for the subsample who
received DrotAA within 24 hours of admission to the critical care
unit. Odds ratio, lifetime costs, QALYs, and incremental net benefits are
shown where DrotAA is given within 24 hours of admission.
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